StevenEKempersMD

Dermatology • New Brighton, MN

Physician

Join to view full profile

Dr. Kempers is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kempers' full profile

Already have an account?

Office
119 14th Street NW, Suite 250
New Brighton, MN 55112
Phone+1 763-571-4200

Fax+1 763-571-7202

Education & Training

University of MinnesotaResidency, Dermatology, 1986 - 1989
Santa Barbara Cottage HospitalInternship, Internal Medicine, 1985 - 1986
Perelman School of Medicine at the University of PennsylvaniaClass of 1985

Certifications & Licensure

CA State Medical License 1986 - 2026
NY State Medical License 2024 - 2026
MN State Medical License 1986 - 2025
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Fellow (FAAD) American Academy of Dermatology

Clinical Trials

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis Start of enrollment: 2007 May 07
Completed
Phase 2
Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris Start of enrollment: 2007 Feb 01
Completed
Phase 3
Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail Start of enrollment: 2007 Jan 01
Completed
Phase 2
Epiduo Pediatric Acne Study Start of enrollment: 2010 Jun 01
Completed
Phase 4
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2010 Aug 01
Completed
Phase 2
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2011 Mar 01
Completed
Phase 3
Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail Start of enrollment: 2011 Jul 01
Completed
Phase 2
Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis Start of enrollment: 2013 Mar 01
Completed
Phase 2
VPD-737 for Treatment of Chronic Pruritus Start of enrollment: 2013 Oct 15
Completed
Phase 2
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities Start of enrollment: 2014 May 01
Completed
Phase 3
Twelve Month Follow-Up of CP0108 Start of enrollment: 2014 Aug 01
Completed
A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris Start of enrollment: 2015 Apr 01
Completed
Phase 2
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Dec 01
Completed
Phase 3
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face Start of enrollment: 2016 Mar 01
Completed
Phase 2
Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat Start of enrollment: 2016 Dec 22
Completed
Phase 2
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp Start of enrollment: 2017 Mar 01
Withdrawn
Phase 3
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period Start of enrollment: 2023 Nov 06
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

2 citations
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
Linda Stein Gold, David N Adam, Lorne Albrecht, Javier Alonso-Llamazares, Laura K Ferris
Journal of the American Academy of Dermatology. 2024-08-01
1 citations
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Kavita Y Sarin, Mark Bradshaw, Chris O'Mara, Jahanbanoo Shahryari, John Kincaid
Science Advances. 2024-05-03
7 citations
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, Michael Bukhalo, Alim R Devani
The British Journal of Dermatology. 2023-09-15

Journal Articles

Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis
Andrew Blauvelt, Steven Kempers, Stephen Tyring, Glynis Ablon, The New England Journal of Medicine
Trial of Roflumilast Cream for Chronic Plaque Psoriasis
Leon H Kircik, Steven E Kempers, Howard Welgus, The New England Journal of Medicine

Authored Content

Trial of Roflumilast Cream for Chronic Plaque PsoriasisJuly 2020

Professional Memberships

American Academy of Dermatology - AAD
Fellow

StevenEKempersMD

Dr. Kempers is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Authored Content

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.